Contribution of bone scintigraphy and PET/CT in the differential diagnosis of bone involvement in a patient with fibrous dysplasia and monoclonal gammopathy of undetermined significance and fibrous dysplasia treatment with denosumab
Authors:
doc. MUDr. Řehák Zdeněk, Ph.D. 1; MUDr. Ptáčník Václav, Ph.D. 2; prof. MUDr. Adam Zdeněk, CSc. 3; MUDr. Koukalová Renata, Ph.D. 1; MUDr. Straub Jan 4; MUDr. Křiva Tomáš 5; MUDr. Adamová Zuzana, Ph.D. 6; MUDr. Křivanová Andrea, Ph.D. 3; MUDr. Boichuk Ivanna 3; prof. MUDr. Pour Luděk, Ph.D. 3
Authors‘ workplace:
Oddělení nukleární medicíny, MOÚ, Brno
1; Ústav nukleární medicíny, 1. LF UK a VFN v Praze
2; Interní hematologická a onkologická klinika LF MU a FN Brno
3; I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze
4; Klinika ústní, čelistní a obličejové chirurgie LF MU a FN Brno
5; Chirurgické oddělení, Moravskoslezská nemocnice Frýdek-Místek, p. o.
6
Published in:
Klin Onkol 2026; 39(4): 294-301
Category:
Case Report
doi:
https://doi.org/10.48095/ccko2026294
Overview
We describe a patient who has both fibrous dysplasia (FD) and monoclonal gammopathy of undetermined significance (MGUS). The simultaneous occurrence of these two pathological conditions is rare, and it is necessary to distinguish whether the bones are being affected by FD or multiple myeloma. The patient‘s problems began with a non-healing tooth extraction, raising suspicion of osteomyelitis. Later, he was also examined for fever of unknown origin, as he had elevated inflammatory markers, low-grade fever, and headaches. According to skeletal scintigraphy, the patient had a craniofacial skeleton affected by FD. Given the presence of IgG lambda type MGUS, it was necessary to rule out transformation of MGUS into multiple myeloma. PET/CT examination with the radiopharmaceuticals sodium fluoride (18F-NaF) and fluorodeoxyglucose (18F-FDG) was used to differentiate this. In the craniofacial skeleton area, the CT image corresponded to FD, and these lesions showed significant NaF accumulation. 18F-FDG accumulation was less pronounced, and none of the lesions with a high 18F-NaF uptake had an osteolytic character, which is indicative of skeletal involvement by FD rather than multiple myeloma. The patient was treated with denosumab, with an initial administration at 28-day intervals and a planned extension of the intervals to 3 months after stabilization of the condition. Immediately after the first denosumab injection, the headaches caused by craniofacial skeletal involvement due to FD disappeared. In the coexistence of MGUS and FD, it is necessary to precisely determine whether the bones are affected by FD or multiple myeloma by using PET/CT imaging and radiopharmaceuticals 18F-NaF and 18F-FDG. The text provides an overview of the drug treatment of FD from a 2026 perspective.
Keywords:
bisphosphonates – denosumab – fibrous dysplasia – MGUS – monoclonal gammopathy of undetermined significance – PET/CT imaging
Sources
1. Křivanová A, Adam Z, Mayer J et al. Teplota nejasné etiologie: příčiny a diagnostický postup, Vnitř Lék 2007; 53 (2): 169–178.
2. Romano Gargarella E, Vocaturo F, Guarneri A et al. Role of 18F FDG-PET-CT in fever and inflammation of unknown origin. J Clin Med 2025; 14 (16): 5861. doi: 10.3390/jcm14165861.
3. Kan Y, Wang W, Liu J et al. Contribution of 18F-FDG PET/CT in a case-mix of fever of unknown origin and inflammation of unknown origin: a meta-analysis. Acta Radiol 2019; 60 (6): 716–725. doi: 10.1177/0284185118799512.
4. Adam Z, Šedivá A, Zeman D et al. Úspěšná léčba SAPHO syndromu (nebakteriální osteomyelitidy a akné) anakinrou a denosumabem. Popis případu a přehled léčebných možností Vnitř Lék 2023; 69 (5): E4–E14. doi: 10.36290/vnl.2023.065.
5. Beran J, Berab J, Beran T. Fibrózní dysplazie v rtg obrazu. Ces Radiol 2024; 78 (3): 164–169. doi: 10.55095/CesRadiol2024/023.
6. Tvrdý P. Vybraná vzácná onemocnění. Fibrózní kostní dysplazie. In: Míšová E, Kratochvílová L, Nocar A et al. Projevy vzácných onemocnění v orofaciální oblasti. Praha: Galén 2024. 256 s.
7. Pečený J Štastný E, Wagenknecht L et al. Fibrózní dysplazie – patofyziologie a ortopedická léčba. Pediatr Praxi 2018; 19 (2): 72–78. doi: 10.36290/ped.2018.015.
8. Zídková H, Kolář J, Matějovský Z et al. Malignizace, či agresivní růst fibrózní kostní dysplazie? Ces Radiol 1993; 47 (3): 139–149.
9. Křiva T, Adam Z, Brumla Z et al. Vnitř Lék 2020; 66 (1): e41–e49. doi: 10.36290/vnl.2020.031.
10. Kurinec F, Rudinský V, Marinčák L. Chirurgická liečba rozsiahlej fibróznej dysplázie v kraniofaciálnej oblasti – kazuistika. Cesk Slov Neurol N 2016; 79 (6): 723–727.
11. Kollerová J, Košťálová Ľ, Koller T et al. McCune-Albrightov syndróm – 11-ročné skúsenosti s liečbou bisfosfonátmi. Clin Osteol 2009; 14 (1): 22–28.
12. Hodan R, Čermáková R, Syrovátka J et al. Fibrózní dysplazie u dětského pacienta léčená bisfosfonáty. Prakt Zub Lék 2008; 56 (4): 45–52.
13. Pazelli AM, Srikumar JK, Gharavi A et al. Skeletal and endocrine manifestations of McCune-Albrightsyndrome in patients with fibrous dysplasia. J Plast Reconstr Aesthet Surg 2025; 109 : 137–143. doi: 10.1016/j.bjps.2025.08.013.
14. Meier ME, Vágó E, Abrahamsen B et al. Incidence and prevalence of fibrous dysplasia/McCune-Albright syndrome: a nationwide registry-based study in Denmark. J Clin Endocrinol Metab 2024; 109 (6): 1423–1432. doi: 10.1210/clinem/dgad744.
15. Palmisano B, Berry C, Boyce A et al. Fibrous dysplasia/McCune-Albrightsyndrome: state-of-the-art advances, pathogenesis, and basic/translational research. Orphanet J Rare Dis 2025; 20 (1): 414. doi: 10.1186/s13023-025-03909-8.
16. Littman JL, Yang W, Feder N et al. The GNAS gene: fibrous dysplasia, McCune-Albrightsyndrome, and skeletal structure and function. Genes (Basel) 2025; 16 (11): 1360. doi: 10.3390/genes16111360.
17. Wentworth KL, Fierro FA, Moody TA et al. Single-cell analysis of human fibrous dysplasia bone reveals a fibrotic transcriptome and GNAS variants in endothelial, perivascular, and stromal cells. Am J Hum Genet 2025; 112 (9): 2067–2087. doi: 10.1016/j.ajhg.2025.07.018.
18. Kim HY, Shim JH, Heo CY. A rare skeletal disorder, fibrous dysplasia: a review of its pathogenesis and therapeutic prospects. Int J Mol Sci 2023; 24 (21): 15591. doi: 10.3390/ijms242115591.
19. Bouet B, Schlund M, De Massary M et al. Craniofacial fibrous dysplasia: systematic review of facial management. J Stomatol Oral Maxillofac Surg 2023; 124 (6 Suppl 2): 101660. doi: 10.1016/j.jormas.2023.101660.
20. Tuompo S, Mäkitie RE, Nieminen MT. Craniofacial fibrous dysplasia: a review of current literature. Bone 2025; 192 : 117377. doi: 10.1016/j.bone.2024.117377.
21. Obermeier KT, Hartung JT, Hildebrandt T et al. Fibrous dysplasia of the jaw: advances in imaging and treatment. J Clin Med 2023; 12 (12): 4100. doi: 10.3390/jcm12124100.
22. Bocán A. Fibrózní dysplazie – monoostotická a polyostotická forma, vzácná forma asociace s McCune-Albright syndromem. Ces Radiol 2024; 78 (4): 241.
23. Song X, Li Z. Co-existing of craniofacial fibrous dysplasia and cerebrovascular diseases: a series of 22 cases and review of the literature. Orphanet J Rare Dis 2021; 16 (1): 471. doi: 10.1186/s13023-021-02102-x.
24. Spencer P, Raturi V, Watters A et al. Pediatric fibrous dysplasia of the skull base: update on management and treatment. Brain Sci 2024; 14 (12): 1210. doi: 10.3390/brainsci14121210.
25. Raborn LN, Pan KS, FitzGibbon EJ et al. Optic disc edema in fibrous dysplasia/McCune-Albrightsyndrome: prevalence, etiologies, and clinical implications. Bone 2021; 143 : 115661. doi: 10.1016/j.bone.2020.115661.
26. Papadakis GZ, Manikis GC, Karantanas AH et al. 18F--NaF PET/CT imaging in fibrou dysplasie of bone. J Bone Miner Res 2019; 34 (9): 1619–1631. doi: 10.1002/jbmr.3738.
27. van der Bruggen W, Hagelstein-Rotman M, de Geus-Oei LF et al. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT. Eur J Nucl Med Mol Imaging 2020; 47 (6): 1527–1537. doi: 10.1007/s00259-019-04657-1.
28. Pozzessere C, Cicone F, Barberio P et al. Cross-sectional evaluation of FGD-avid polyostotic fibrous dysplasia: MRI, CT and PET/MRI findings. Eur J Hybrid Imaging 2022; 6 (1): 19. doi: 10.1186/s41824-022-00139-0.
29. Wang Y, Wu J, Liu L et al. 68Ga-FAPI-04 PET/CT imaging for fibrous dysplasia of the bone. Clin Nucl Med 2022; 47 (1): e9–e10. doi: 10.1097/RLU.0000000000003896.
30. Mu X, Li Z, Qin J et al. Comparison of 18 F-FAPI and 18 F-FDG PET/CT in a patient with fibrous dysplasia. Clin Nucl Med 2024; 49 (4): e182–e183. doi: 10.1097/RLU.0000000000005089.
31. Rehak Z, Bencsikova B, Zambo I et al. Fibrous dysplasia presenting as a cold spot in 18F-FLT PET/CT imaging. Clin Nucl Med 2016; 41 (6): 510–511. doi: 10.1097/RLU.0000000000001209.
32. Tamsel I, Kocabeyoglu B, Hekimsoy I et al. The radiologic and FDG uptake findings of osseous lesions incidentally detected on 18F-FDG-PET/CT imaging. Acta Radiol 2025; 66 (10): 1029–1035. doi: 10.1177/02841851251339019.
33. Pereira TDSF, Gomes CC, Brennan PA et al. Fibrous dysplasia of the jaws: integrating molecular pathogenesis with clinical, radiological, and histopathological features. J Oral Pathol Med 2019; 48 (1): 3–9. doi: 10.1111/jop.12797.
34. Chebib I, Chang CY, Lozano-Calderon S. Fibrous and fibro-osseous lesions of bone. Surg Pathol Clin 2021; 14 (4): 707–721. doi: 10.1016/j.path.2021.06.011.
35. Levaillant L, Mabilleau G, Malagié A et al. Comparison of traditional and new treatments for fibrous dysplasia: a systematic review and meta-analysis. Osteoporos Int 2026. [Ahead of Print]. doi: 10.1007/s00198-026-07918-6.
36. Bertin H, Moussa MS, Komarova S. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis. Rev Endocr Metab Disord 2023; 24 (6): 1103–1119. doi: 10.1007/s11154-023-09832-2.
37. Tucker-Bartley A, Selen DJ, Golden E et al. Pharmacological interventions targeting pain in fibrous dysplasia/McCune-Albright syndrome. Int J Mol Sci 2023; 24 (3): 2550. doi: 10.3390/ijms24032550.
38. Wentworth KL, Park J, Yu X et al. Update on the medical management of fibrous dysplasia of the bone. Ther Adv Endocrinol Metab 2025; 16 : 20420188251347350. doi: 10.1177/20420188251347350.
39. Valadares LP, de Araújo Ferreira BS, da Cunha BM et al. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience. Arch Endocrinol Metab 2022; 66 (2): 247–255. doi: 10.20945/2359-3997000000459.
40. Bansal K, Prasad A, Singh S et al. Pathological femoral shaft fracture with McCune-Albright syndrome with hyperthyroidism managed with oral alendronate: a case report. Cureus 2022; 14 (7): e26802. doi: 10.7759/cureus.26802.
41. Nadella S, Mupparapu M, Akintoye SO. Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature. Quintessence Int 2022; 53 (7): 616–623. doi: 10.3290/j.qi.b3082785.
42. de Castro LF, Whitlock JM, Michel Z et al. RANKL Inhibition reduces lesional cellularity and ga. Bone Res 2024; 12 (1): 10. doi: 10.1038/s41413-023-00311-7.
43. de Castro LF, Michel Z, Pan K et al. Safety and efficacy of denosumab for fibrous dysplasia of bone. N Engl J Med 2023; 388 (8): 766–768. doi: 10.1056/NEJMc2214862.
44. Szymczuk V, Elbashir II, Ahmed R et al. Safety and efficacy of moderate-dose denosumab in fibrous dysplasia: observational results from a phase 2 clinical trial. J Clin Endocrinol Metab 2025; 110 (9): 2666–2673. doi: 10.1210/clinem/dgae867.
45. Meier ME, van der Bruggen W, van de Sande MAJ et al. Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases. Bone Rep 2021; 14 : 101058. doi: 10.1016/j.bonr.2021.101058.
46. Hung C, Shibli-Rahhal A. Denosumab use in adults with fibrous dysplasia: case reports and review of the literature. Endocr Pract 2022; 28 (11): 1196–1201. doi: 10.1016/j.eprac.2022.07.012.
47. Huzum B, Antoniu S, Dragomir R. Treatment of fibrous dysplasia: focus on denosumab. Expert Opin Biol Ther 2022; 22 (3): 397–405. doi: 10.1080/14712598.2022.2022118.
48. Ikuta K, Sakai T, Koike H et al. Successful treatment with denosumab for pelvic fibrous dysplasia: a case report and review of the literature. Medicine (Baltimore) 2021; 100 (49): e28138. doi: 10.1097/MD.0000000000028138.
49. Yau V, Best DL. Efficacy of denosumab for treatment of pain in fibrous dysplasia and McCune-Albright syndrome: a systematic review. Clin Endocrinol (Oxf) 2026; 105 (2): 141–150. doi: 10.1111/cen.70133.
50. Meier ME, Clerkx SN, Winter EM et al. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res 2021; 36 (9): 1729–1738. doi: 10.1002/jbmr.4380.
51. Liu D, Chen J, Chen H et al. Rebound hypercalcemia after denosumab cessation in adult fibrous dysplasia: a case report and clinical alert. Case Rep Endocrinol 2025; 2025 : 4553039. doi: 10.1155/crie/4553039.
52. Majoor BCJ, Papapoulos SE, Dijkstra PDS et al. Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates. J Clin Endocrinol Metab 2019; 104 (12): 6069–6078. doi: 10.1210/jc.2018-02543.
53. Trojani MC, Gensburger D, Bagouet F et al. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: a retrospective multicentric study. Bone 2023; 174 : 116819. doi: 10.1016/j.bone.2023.116819.
54. van der Bruggen W, Vriens D, Meier ME et al. Denosumab reduces lesional fluoride skeletal burden on na18ff PET-CT in patients with fibrous dysplasia/McCune-Albright syndrome. J Clin Endocrinol Metab 2021; 106 (8): e2980–e2994. doi: 10.1210/clinem/dgab212.
55. Wang D, Tang X, Shi Q et al. Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review. Transl Pediatr 2023; 12 (3): 470–486. doi: 10.21037/tp-22-276.
56. Eller-Vainicher C, Rossi DS, Guglielmi G et al. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia. Clin Cases Miner Bone Metab 2016; 13 (3): 253–256. doi: 10.11138/ccmbm/2016.13.3.253.
57. Treglerová J, Zelinka J, Adam Z et al. Osteonekróza čelisti, atypické fraktury kostí a další méně časté nežádoucí účinky bisfosfonátů. Transfuze Hemat Dnes 2019; 25 (3): 242–251.
58. Goyal A, Tandon N. Burosumab: current status and future prospects. Best Pract Res Clin Endocrinol Metab 2024; 38 (2): 101826. doi: 10.1016/j.beem.2023.101826.
59. Lamb YN. Burosumab: first global approval. Drugs 2018; 78 (6): 707–714. doi: 10.1007/s40265-018-0905-7.
60. Gladding A, Szymczuk V, Auble BA et al. Burosumab treatment for fibrous dysplasia. Bone 2021; 150 : 116004. doi: 10.1016/j.bone.2021.116004.
61. Sakka SD, Georgakopoulou D, Doulgeraki A et al. Burosumab treatment of a child with McCune-Albright syndrome/polyostotic fibrous dysplasia: challenges and benefits. JBMR Plus 2025; 9 (5): ziaf042. doi: 10.1093/jbmrpl/ziaf042.
62. Pečený J, Štastný E, Wagenknecht L et al. Fibrózní dysplazie – patofyziologie a ortopedická léčba. Pediatr Praxi 2018; 19 (2): 72–78. doi: 10.36290/ped.2018.015.
63. Stelmachowska-Banaś M, Cylke-Falkowska K, Zgliczyński W et al. Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune-Albright syndrome: case report and review of the literature. JBMR Plus 2025; 9 (9): ziaf125. doi: 10.1093/jbmrpl/ziaf125.
64. de Jong O, Gun ZH, Asante-Otoo A et al. A phase 2 trial of burosumab for treatment of fibroblast growth factor-23 mediated hypophosphatemia in children and adults with fibrous dysplasia. medRxiv 2025. [Preprint]. doi: 10.1101/2025.09.26.25334161.
65. de Boysson H, Johnson A, Hablani N et al. Tocilizumab in the treatment of a polyostotic variant of fibrous dysplasia of bone. Rheumatology (Oxford) 2015; 54 (9): 1747–1749. doi: 10.1093/rheumatology/kev221.
66. Chapurlat R, Gensburger D, Trolliet C et al. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: the randomized double-blind placebo-controlled TOCIDYS trial. Bone 2022; 157 : 116343. doi: 10.1016/j.bone.2022.116343.
67. Fighera TM, Spritzer PM. Effect of intranasal calcitonin in a patient with McCune-Albright syndrome, fibrous dysplasia, and refractory bone pain. Case Rep Endocrinol 2017; 2017 : 7898713. doi: 10.1155/2017/7898713.
68. Schreuder WH, Meijer EB, Cleven AHG et al. Efficacy and toxicity of calcitonin treatment in children with cherubism: a single-center cohort study. J Bone Miner Res 2023; 38 (12): 1822–1833. doi: 10.1002/jbmr.4922.
69. Palot Manzil FF, Suthar P, Vattoth S. Fibrous dysplasia of frontal process of maxilla: false-positive finding on. J Nucl Med Technol 2025. [Ahead of Print]. doi: 10.2967/jnmt.125.270668.
70. Furmah P, Aminoshariae A, Mupparapu M et al. Frequency of spontaneous osteosarcomatous transformation of craniofacial fibrous dysplasia: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 2023; 135 (5): 678–685. doi: 10.1016/j.oooo.2022.12.007.
71. Shi R, Li X, Zhang J et al. Clinicopathological and genetic study of a rare occurrence: malignant transformation of fibrous dysplasia of the jaws. Mol Genet Genomic Med 2022; 10 (1): e1861. doi: 10.1002/mgg3.1861.
72. Liu L, Sun J, Liu S et al. Malignant transformation of craniofacial fibrous dysplasia: a clinicopathological, immunohistochemical and molecular analysis of 15 cases in one single institution. J Stomatol Oral Maxillofac Surg 2025; 126 (3): 102098. doi: 10.1016/j.jormas.2024.102098.
73. Sandecká V, Pour L, Adam Z et al. Monoclonal gammopathy of undetermined significance (MGUS). Klin Onkol 2018; 31 (4): 270–276. doi: 10.14735/amko2018270.
74. Tsuyuguchi N, Ohata K, Morino M et al. Magnetic resonance imaging and [11C]methyl-L-methionine positron emission tomography of fibrous dysplasia – two case reports. Neurol Med Chir 2002; 42 (8): 341–345. doi: 10.2176/nmc.42.341.
75. Gu CN, Hunt CH, Lehman VT et al. Benign fibrous dysplasia on [ (11) C]choline PET: a potential mimicker of disease in patients with biochemical recurrence of prostate cancer. Ann Nucl Med 2012; 26 (7): 599–602. doi: 10.1007/s12149-012-0610-7.
76. Kagna O, Pirmisashvili N, Tshori S et al. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants. AJR Am J Roentgenol 2014; 203 (6): 1317–1323. doi: 10.2214/AJR.14.12588.
77. Kagna O, Pirimisashvili N, Tshori S et al. Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants. AJR Am J Roentgenol 2014; 203 (6): 1317–1323. doi: 10.2214/AJR.14.12588.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2026 Issue 4
Most read in this issue
- Treatment of Erdheim-Chester disease from the perspective in 2026
- Evaluation of ice ball size as a function of freezing intensity through computed tomography scans during cryoablation procedures
- Dlouhá cesta k RAS (on) inhibitoru
- IgG4-related disease – treatment with anti-CD20, anti-CD19 antibodies, and other new drugs